Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Paul Siffri

Orthopaedic Surgery Greenville, SC Medical Doctor

NPI 1649223355 CMS profile 165544

200 Patewood Dr Ste C100, Greenville, SC 29615

Open in the dashboard

General payments

$9,474

38 records reported · program years 2019–2025

Research payments

$25,943

Paid to them · 2 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Paul Siffri of Greenville, SC is reported in the CMS Open Payments database as having received $9,474 across 38 general payments and $25,943 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $496 5
2024 General $503 4
2023 General $444 3
2022 General $2,637 4
2021 General $1,771 6
2020 General $2,067 10
2020 Research $25,943 2
2019 General $1,557 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Paul Siffri
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Paul Siffri were reported at $496. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Paul Siffri Orthopaedic Surgery median Middle half National median
2019 $1,557 $644 $140–$2,844 $163
2020 $2,067 $312 $75–$1,860 $114
2021 $1,771 $520 $117–$2,495 $132
2022 $2,637 $598 $128–$2,731 $149
2023 $444 $461 $128–$2,264 $160
2024 $503 $497 $134–$2,475 $164
2025 $496 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Peerless Surgical Inc. $5,524 8 payments
  2. Arthrex, Inc. $1,013 4 payments
  3. Anika Therapeutics, Inc. $893 6 payments
  4. Stryker Corporation $371 3 payments
  5. Innovation Technologies Inc $246 2 payments
  6. Smith+Nephew, Inc. $223 5 payments
  7. Miach Orthopaedics, Inc. $184 1 payment
  8. Argentum Medical $170 1 payment
  9. Avanos Medical $149 2 payments
  10. Biom'Up France SAS $147 1 payment
  11. Other $556 5 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Education $5,316 5 payments
  2. Food and Beverage $3,158 30 payments
  3. Travel and Lodging $1,001 3 payments
Products named General payments · program years 2019–2025
  1. Integrity $303 2 payments
  2. Tactoset $295 2 payments
  3. Irrisept $246 2 payments
  4. BLUEPRINT PATIENT SPECIFIC INSTRUMENTATION $174 1 payment
  5. REUNION $174 1 payment
  6. ULTRABUTTON $174 3 payments
  7. NOVOSTITCH $166 2 payments
  8. Integrity Implant $153 1 payment
  9. ON-Q* PUMP AND ACCESSORIES $149 2 payments
  10. HEMOBLAST BELLOWS $147 1 payment
  11. Other $1,265 13 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Integra LifeSciences Corporation $25,943 2 payments

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

683

Median for Sports Medicine: 144

Drug cost

$5,552

Median for Sports Medicine: $1,027

Branded share of claims

2.9%

Median for Sports Medicine: 0%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Lidocaine Generic 49 $3,371
Methylprednisolone Generic 250 $979
Oxycodone Hcl Generic 55 $232
Diclofenac Sodium Generic 32 $223
Meloxicam Generic 104 $199
Celecoxib Generic 20 $197
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 20 $153
Tramadol Hcl Generic 35 $51
Gabapentin Generic 14 $39
Amoxicillin Generic 68 $39

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,691 Part D prescribers listed as Sports Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 46 billing codes

Paid by Medicare

$165,673

Of which drugs: $10,093

Medicare patients

552

Average age 73

Services billed

5,001

283 women, 269 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 28%
Ischemic heart disease 25%
Depression 24%
Chronic kidney disease 22%
Osteoporosis 15%
Atrial fibrillation 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, durolane, for intra-articular injection, 1 mg J7318 Office 12 1,020 $4,914
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 293 1,744 $1,268

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

40 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record